home All News open_in_new Full Article

AAD 2025: Galderma to Present Extensive Updates From Across Its Dermatology Portfolio, Demonstrating Its Category Leadership and Strong Momentum

New data on Nemluvio® (nemolizumab), including an oral e-poster presentation characterizing the impact of Nemluvio in different pruriginous lesion types in prurigo nodularis from the phase III OLYMPIA program, and post-hoc analyses exploring the continuous response of Nemluvio up to 56 weeks in atopic dermatitis patients from the ARCADIA 1&2 trials and long-term extension study […]


today last month attach_file Politics

attach_file Politics
attach_file Other
attach_file Economics
attach_file Sport
attach_file Other
attach_file Politics


ID: 2273916428
Add Watch Country

arrow_drop_down